Credit Suisse Ag Glycomimetics Inc Transaction History

Credit Suisse Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$4.03 - $6.5 $124,313 - $200,505	-30,847 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$2.8 - $12.85 $21,921 - $100,602	7,829 Added 34.01%	30,847 $133,000
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $15,984 - $19,784	-1,508 Reduced 6.15%	23,018 $274,000
Q1 2019 May 14, 2019	SELL	$9.96 - $13.44 $136,461 - $184,141	-13,701 Reduced 35.84%	24,526 $306,000
Q4 2018 Feb 13, 2019	BUY	$8.47 - $14.71 $59,476 - $103,293	7,022 Added 22.5%	38,227 $362,000
Q3 2018 Nov 13, 2018	SELL	$13.7 - $17.12 $144,452 - $180,513	-10,544 Reduced 25.26%	31,205 $449,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $596,933 - $782,990	-40,802 Reduced 49.43%	41,749 $674,000
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $1.13 Million - $1.79 Million	70,626 Added 592.25%	82,551 $1.34 Million
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $125,331 - $205,348	11,925 New	11,925 $200,000
Q3 2017 Nov 14, 2017	SELL	$10.14 - $14.85 $173,495 - $254,083	-17,110 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	17,110	17,110 $191,000

27.3M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $15.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.